EQUITY RESEARCH MEMO

DRG International

Generated 5/10/2026

Executive Summary

Conviction (model self-assessment)65/100

DRG International, Inc. is a leading global manufacturer and supplier of in-vitro diagnostic (IVD) immunoassays and laboratory equipment. Founded in 1970 and headquartered in Springfield, New Jersey, the company offers a broad portfolio of ELISA kits, automated analyzers, and diagnostic media for clinical and research applications. With operations spanning over 110 countries through offices and distributors, DRG has established a strong international footprint. The company's long-standing presence and comprehensive product line position it as a reliable partner in the diagnostics market. However, as a private entity, DRG does not disclose financials or detailed pipeline updates, limiting visibility into near-term growth drivers.

Upcoming Catalysts (preview)

  • Q3 2026Launch of next-generation automated ELISA analyzer70% success
  • TBDFDA clearance for a novel infectious disease immunoassay55% success
  • Q3 2026Expansion into emerging market (e.g., India or Brazil) through new distributor partnerships80% success
Locked sections
  • · Pipeline Analysis
  • · Competitive Landscape
  • · Catalyst Calendar (full 12-month)
  • · Bull Case
  • · Bear Case
  • · Counterfactual Scenarios
  • · Valuation Notes
  • · SEC Filing Highlights
  • · Insider Activity
  • · Literature Watch
  • · Patent Landscape
  • · Mechanism Cluster Map
  • · Audio Briefing (5 min)